These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1283494)

  • 1. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Scher HI; Curley T; Yeh S; Tong W; O'Moore PV; Larson S
    Adv Exp Med Biol; 1992; 324():115-29. PubMed ID: 1283494
    [No Abstract]   [Full Text] [Related]  

  • 2. Pain palliation and nuclear medicine.
    McEwan AJ
    Eur J Nucl Med; 1993 Jan; 20(1):1-3. PubMed ID: 7678395
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    Koutsikos J; Leondi A
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted radionuclide therapy for bone metastases.
    Lewington VJ
    Eur J Nucl Med; 1993 Jan; 20(1):66-74. PubMed ID: 7678397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W; Kampen WU; Kampen AM; Henze E
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals.
    Ketring AR
    Int J Rad Appl Instrum B; 1987; 14(3):223-32. PubMed ID: 3117736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
    Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR
    J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
    Sandeman TF; Budd RS; Martin JJ
    Clin Oncol (R Coll Radiol); 1992 May; 4(3):160-4. PubMed ID: 1375094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EANM procedure guidelines for treatment of refractory metastatic bone pain.
    Silberstein EB; Taylor AT;
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP7-11. PubMed ID: 12723557
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
    Weiss K; Köck HH; Atefie K; Sinzinger H
    Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421
    [No Abstract]   [Full Text] [Related]  

  • 12. Samarium-153 lexidronam for painful bone metastases.
    Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in our understanding of the treatment of painful bone metastasis.
    Siberstein EB
    J Nucl Med; 2000 Apr; 41(4):655-7. PubMed ID: 10809605
    [No Abstract]   [Full Text] [Related]  

  • 14. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S; Bohuslavizki KH
    MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
    Liepe K; Kropp J; Hliscs R; Franke WG
    Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma.
    De Winter F; Brans B; Van De Wiele C; Dierckx RA
    Clin Nucl Med; 1999 Nov; 24(11):898-9. PubMed ID: 10551482
    [No Abstract]   [Full Text] [Related]  

  • 18. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB
    J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.